Fusion Pharmaceuticals’ $212.5 Million Initial Public Offering


Latham & Watkins LLP represented the underwriters in the initial public offering.

Fusion Pharmaceuticals Inc. has announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17.00 per share. All of the shares are being offered by Fusion. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Fusion, are expected to be $212.5 million. In addition, Fusion has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 common shares at the initial public offering price.

Morgan Stanley, Jefferies, and Cowen acted as joint book-running managers for the offering. Wedbush PacGrow acted as lead manager for the offering.

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.

Latham & Watkins LLP represented the underwriters in the initial public offering with a capital markets team led by partners Peter Handrinos (Picture) and Wesley Holmes, with associates Adam Johnson, Angel Marcial and Tyler Mills.

Involved fees earner: Peter Handrinos – Latham & Watkins; Wesley Holmes – Latham & Watkins; Adam Johnson – Latham & Watkins; Angel Marcial – Latham & Watkins; Tyler David Mills – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Cowen and Company; Jefferies; Morgan Stanley; Wedbush PacGrow;

Author: Ambrogio Visconti